GeneNews announces Dundee Wealth to offer ColonSentry(TM) to its employees

TORONTO, May 6 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement with DundeeWealth Inc., a leading Canadian wealth management firm, to offer ColonSentry(TM) to its employees.

"At DundeeWealth, maintaining and promoting health and wellness is a top priority - the ColonSentry(TM) test is perfectly aligned with this focus," said Dr. David Doull, Director, Human Resources Programs & Administration, DundeeWealth Inc. "Early detection of colorectal cancer benefits both our employees and the firm."

"DundeeWealth's desire to offer ColonSentry(TM), the world's first blood test for colorectal cancer, supports their commitment to the health of their employees and is a great example where our product can be a benefit to both employees and the employer," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "As evidenced by the health economic analysis we recently reported, incorporating the ColonSentry(TM) test into a colorectal cancer screening program is a cost-effective strategy to help preserve an organization's investment in human capital and protect them from costly healthcare, disability and life claims related to late stage colorectal cancer. This agreement reflects a component of our ColonSentry(TM) commercialization strategy and we look forward to working with other firms to include the ColonSentry(TM) test in their employee programs."

    
    About GeneNews
    --------------
    

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews and the ColonSentry(TM) test, visit www.genenews.com and www.colonsentry.com.

    
    About DundeeWealth Inc.
    -----------------------
    

DundeeWealth is a Canadian owned, independent wealth management company that oversees $55.2 billion in fee earning assets. It provides diversified wealth management and investment solutions including alternative and tax-advantaged products, capital markets and advisory services to financial advisors, institutions, corporations and foundations, and innovative wealth management through independent financial advisors across Canada. Its award winning investment brand, Dynamic Funds, managed by Goodman & Company, Investment Counsel Ltd., is also available outside of Canada through distribution platforms in Europe and the United States. DundeeWealth is listed on the Toronto Stock Exchange (TSX: DW).

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE GeneNews Limited

For further information: For further information: Casey Gurfinkel, (416) 815-0700 x 283, cgurfinkel@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890